50 likes | 58 Views
(Albany, NY) DelveInsight has launched a new report on u201cBipolar Depression Market Insight, Epidemiology and Market Forecast -2030.u201d<br><br>DelveInsight's "Bipolar Depression Market Insights and Forecast Report" delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends, pipeline scenario, Bipolar Depression market drivers, barriers, and forecasted analysis in the 7MM for the study period 2017-30.<br><br>Some of the Facts:<br>u2022tAs per DelveInsight analysts, the total diagnosed prevalent population of Bipolar Depression in the 7MM was 1,857,545 in 2017.<br>u2022tThe estimates show the highest diagnosed prevalence of Bipolar Depression in the United States with 740,715 cases in 2017.<br>u2022tBipolar I and Bipolar II are the major subtypes of BD. <br>u2022tIn 2017, out of the total diagnosed prevalent population of 740,715 cases in the US for Bipolar Depression, 291,134 and 449,581 cases were contributed by Bipolar I disorder and Bipolar II disorder, respectively.
E N D
Bipolar Depression Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight (Albany, NY) DelveInsight has launched a new report on “Bipolar Depression Market Insight, Epidemiology and Market Forecast -2030.” DelveInsight's "Bipolar Depression Market Insights and Forecast Report" delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends, pipeline scenario, Bipolar Depression market drivers, barriers, and forecasted analysis in the 7MM for the study period 2017-30. Some of the Facts: As per DelveInsight analysts, the total diagnosed prevalent population of Bipolar Depression in the 7MM was 1,857,545 in 2017. The estimates show the highest diagnosed prevalence of Bipolar Depression in the United States with 740,715 cases in 2017. Bipolar I and Bipolar II are the major subtypes of BD. In 2017, out of the total diagnosed prevalent population of 740,715 cases in the US for Bipolar Depression, 291,134 and 449,581 cases were contributed by Bipolar I disorder and Bipolar II disorder, respectively. Scope of the Report: The Bipolar Depression report covers the descriptive overview of Bipolar Depression, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies Comprehensive insight has been provided into the Bipolar Depression epidemiology and treatment in the 7MM Additionally, an all-inclusive account of both the current and emerging therapies for Bipolar Depression are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Bipolar Depression market; historical and forecasted is included in the report, covering drug outreach in the 7MM The Bipolar Depression report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bipolar Depression market Request for Free Sample Report: https://www.delveinsight.com/sample-request/bipolar-disorder- manic-depression-market Bipolar Depression (Manic depression) is categorized by recurrent-shifts in the mood/temper and is a manic-depressive disorder hindering the routine life of an individual. The American Psychiatric Association categorizes Bipolar Depression into four major types of Bipolar Depression: Bipolar I disorder, Bipolar II disorder, Cyclothymic disorder, and Bipolar Depression due to another medical or substance abuse disorder. Bipolar Depression affects about 45 million people worldwide, says WHO. Bipolar Depression Market: Marketed, and Upcoming Drugs FDA-approved agents for the acute treatment of bipolar depression include Olanzapine-fluoxetine combination, Lurasidone, and Quetiapine. Other off-label therapies present in the Bipolar Depression market are Anticonvulsants (such as Divalproex and lamotrigine), olanzapine monotherapy, and Lithium and lamotrigine combined therapy. The Bipolar Depression market report covers detailed picture of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. The report helps in providing a better understanding of clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Request for Free Sample Report: https://www.delveinsight.com/sample-request/bipolar-disorder- manic-depression-market Drugs Covered are: Vraylar (Cariprazine) Latuda (Lurasidone Hydrochloride) Abilify (Aripiprazole) Lumateperone/ITI-007 NRX-100/NRX-101 Psilocybin Zuranolone (SAGE-217) SEP-4199 ILT101
Falkieri (Esketamine DPI) And Many Others Some of the Key Companies Covered: Allergan (AbbVie)/Gedeon Richter Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma) Otsuka Pharmaceutical Intra-cellular Therapies NeuroRx COMPASS Pathways Sage Therapeutics Sunovion/Sumitomo Dainippon Pharma Iltoo Pharma Celon Pharma And Many Others Request for Free Sample Report: https://www.delveinsight.com/sample-request/bipolar-disorder- manic-depression-market Bipolar Depression Report Highlights Dynamic Bipolar Depression market trends Healthcare spending fuelling Bipolar Depression Market Collaborations, mergers, and acquisitions in Market Challenges poised and opportunities present influencing Bipolar Depression Market R&D driving Market Novel therapies and drugs in Bipolar Depression pipeline Major players involved impacting Bipolar Depression market In-depth analysis of the pipeline products (Phase III and Phase II), comparative analysis with detailed clinical profiles, key cross-competition, launch date along with product development activities Request for Free Sample Report: https://www.delveinsight.com/sample-request/bipolar-disorder- manic-depression-market Table of Contents 1. Key Insights
2. Executive Summary of Bipolar Depression 3. Competitive Intelligence Analysis for Bipolar Depression 4. Bipolar Depression: Market Overview at a Glance 5. Bipolar Depression: Disease Background and Overview 6. Patient Journey 7. Bipolar Depression Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Unmet Needs 10. Key Endpoints of Bipolar Depression Treatment 11. Marketed Products 12. Emerging Therapies 13. Bipolar Depression: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of Bipolar Depression 17. KOL Views 18. Market Drivers 19. Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer Request for Detailed TOC: https://www.delveinsight.com/sample-request/bipolar-disorder- manic-depression-market About DelveInsight DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for Browse through our vast repository from here.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: info@delveinsight.com Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/ Bipolar Depression market,Bipolar Depression market research,Bipolar Depression market insight,Bipolar Depression market trends,Bipolar Depression market forecast,Bipolar Depression market share,Bipolar Depression pipeline drugs,Bipolar Depression treatment algorithm,Bipolar Depression drugs,Bipolar Depression sales forecasting,Bipolar Depression market size,Bipolar Depression disease,Bipolar Depression epidemiology,Bipolar Depression